MX2016001030A - Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico. - Google Patents
Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.Info
- Publication number
- MX2016001030A MX2016001030A MX2016001030A MX2016001030A MX2016001030A MX 2016001030 A MX2016001030 A MX 2016001030A MX 2016001030 A MX2016001030 A MX 2016001030A MX 2016001030 A MX2016001030 A MX 2016001030A MX 2016001030 A MX2016001030 A MX 2016001030A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- desmopressin
- beta
- combination
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 title abstract 2
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 title abstract 2
- 229960004281 desmopressin Drugs 0.000 title abstract 2
- 229940126158 β3 adrenergic receptor agonist Drugs 0.000 title abstract 2
- 206010036018 Pollakiuria Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010029446 nocturia Diseases 0.000 abstract 1
- 208000022934 urinary frequency Diseases 0.000 abstract 1
- 230000036318 urination frequency Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361857431P | 2013-07-23 | 2013-07-23 | |
| PCT/US2014/047899 WO2015013454A1 (en) | 2013-07-23 | 2014-07-23 | Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016001030A true MX2016001030A (es) | 2016-10-07 |
Family
ID=51299056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001030A MX2016001030A (es) | 2013-07-23 | 2014-07-23 | Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9814753B2 (enExample) |
| EP (1) | EP3024474B1 (enExample) |
| JP (2) | JP2016525548A (enExample) |
| KR (3) | KR20240015735A (enExample) |
| CN (1) | CN105579057A (enExample) |
| AU (1) | AU2014293141A1 (enExample) |
| CA (1) | CA2919198A1 (enExample) |
| DK (1) | DK3024474T3 (enExample) |
| ES (1) | ES2910361T3 (enExample) |
| MX (1) | MX2016001030A (enExample) |
| WO (1) | WO2015013454A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0623838D0 (en) * | 2006-11-29 | 2007-01-10 | Malvern Cosmeceutics Ltd | Novel compositions |
| CA2765221C (en) * | 2009-06-18 | 2017-10-03 | Allergan, Inc. | Safe desmopressin administration |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| EP3024473A1 (en) | 2013-07-23 | 2016-06-01 | Allergan, Inc. | Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor |
| CN105579057A (zh) * | 2013-07-23 | 2016-05-11 | 阿勒根公司 | 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物 |
| CA2967390A1 (en) | 2014-11-20 | 2016-05-26 | Allergan, Inc. | Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist |
| MX2017007054A (es) | 2014-12-03 | 2018-05-02 | Velicept Therapeutics Inc | Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior. |
| WO2017210700A1 (en) * | 2016-06-03 | 2017-12-07 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
| KR101877834B1 (ko) * | 2017-04-27 | 2018-07-12 | 주식회사 다산제약 | 미라베그론의 신규한 염 및 이의 제조방법 |
| CN112587508A (zh) * | 2020-12-20 | 2021-04-02 | 北京君和为医药科技有限公司 | 一种米拉贝隆透皮贴剂 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH495957A (de) | 1966-09-15 | 1970-09-15 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4316893A (en) | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US4557934A (en) | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
| NZ241979A (en) | 1991-03-20 | 1996-01-26 | Merck & Co Inc | Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| WO1999027905A1 (en) | 1997-12-02 | 1999-06-10 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited | Compositions for nasal administration |
| US7335186B2 (en) | 1998-03-13 | 2008-02-26 | Alexander George Brian O'Neil | Patient controlled drug delivery device |
| US6558695B2 (en) | 1999-12-16 | 2003-05-06 | Dermatrends, Inc. | Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers |
| WO2002055128A2 (en) | 2000-11-30 | 2002-07-18 | Biovalve Technologies Inc | Fluid delivery and measurement systems and methods |
| US7244703B2 (en) | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
| GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
| US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
| CA2503570C (en) * | 2002-11-07 | 2011-04-19 | Yamanouchi Pharmaceutical Co., Ltd. | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
| WO2005046707A1 (en) | 2003-11-10 | 2005-05-26 | Fein Seymour H | Pharmaceutical compositions including low dosages of desmopressin |
| JP2007513199A (ja) | 2003-12-08 | 2007-05-24 | ベントレー ファーマスーティカルス，インコーポレイテッド | インスリン治療のための薬学的組成物及び方法 |
| DE102005016981A1 (de) | 2005-04-13 | 2006-10-19 | Bayer Healthcare Ag | Kombination zur Therapie bei benigner Prostatahyperplasie |
| WO2007072156A1 (en) | 2005-12-21 | 2007-06-28 | Pfizer Products Inc. | Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor |
| JPWO2007083640A1 (ja) * | 2006-01-18 | 2009-06-11 | 杏林製薬株式会社 | 頻尿及び尿失禁の予防又は治療剤 |
| WO2009021007A1 (en) | 2007-08-06 | 2009-02-12 | Serenity Pharmaceuticals Corporation | Methods and devices for desmopressin drug delivery |
| CN101648017A (zh) | 2008-08-12 | 2010-02-17 | 许洁 | 用于治疗泌尿生殖系统及下尿路疾病的联合药物组合物 |
| WO2010028211A1 (en) | 2008-09-04 | 2010-03-11 | Rozmanith Anthony I | Health care |
| SG10201509152VA (en) * | 2008-12-22 | 2015-12-30 | Allergan Inc | Intranasal desmopressin administration |
| US20100160214A1 (en) | 2008-12-22 | 2010-06-24 | Serenity Pharmaceuticals Corporation | Desmopressin composition |
| CA2765221C (en) * | 2009-06-18 | 2017-10-03 | Allergan, Inc. | Safe desmopressin administration |
| US20120202819A1 (en) * | 2009-10-07 | 2012-08-09 | Merck Sharp & Dohme Corporation | Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent |
| US9119878B2 (en) | 2010-07-08 | 2015-09-01 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| US9522129B2 (en) * | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| EP2907504B1 (en) | 2011-02-08 | 2017-06-28 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
| NZ712594A (en) | 2012-03-19 | 2016-09-30 | Wellesley Pharmaceuticals Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
| TW201422254A (zh) | 2012-11-21 | 2014-06-16 | Ferring Bv | 用於速釋及延釋的組成物 |
| GB201312155D0 (en) | 2013-07-05 | 2013-08-21 | Ucl Business Plc | Therapeutic invention |
| CN105579057A (zh) | 2013-07-23 | 2016-05-11 | 阿勒根公司 | 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物 |
| EP3024473A1 (en) | 2013-07-23 | 2016-06-01 | Allergan, Inc. | Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor |
| US20160220489A1 (en) | 2013-09-03 | 2016-08-04 | G2B Pharma Inc. | Intranasal Formulation for the Treatment of Cardiopulmonary Resuscitation (CPR), Cardiac Life Support (CLS), Anaphylaxis and/or Anaphylactoid Reactions |
| CA2967390A1 (en) | 2014-11-20 | 2016-05-26 | Allergan, Inc. | Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist |
-
2014
- 2014-07-23 CN CN201480052301.7A patent/CN105579057A/zh active Pending
- 2014-07-23 AU AU2014293141A patent/AU2014293141A1/en not_active Abandoned
- 2014-07-23 MX MX2016001030A patent/MX2016001030A/es unknown
- 2014-07-23 US US14/338,554 patent/US9814753B2/en not_active Expired - Fee Related
- 2014-07-23 EP EP14748451.3A patent/EP3024474B1/en active Active
- 2014-07-23 JP JP2016529872A patent/JP2016525548A/ja active Pending
- 2014-07-23 KR KR1020247002750A patent/KR20240015735A/ko not_active Ceased
- 2014-07-23 ES ES14748451T patent/ES2910361T3/es active Active
- 2014-07-23 WO PCT/US2014/047899 patent/WO2015013454A1/en not_active Ceased
- 2014-07-23 DK DK14748451.3T patent/DK3024474T3/da active
- 2014-07-23 CA CA2919198A patent/CA2919198A1/en active Pending
- 2014-07-23 KR KR1020167004515A patent/KR20160033220A/ko not_active Ceased
- 2014-07-23 KR KR1020217025792A patent/KR20210103589A/ko not_active Ceased
-
2017
- 2017-11-13 US US15/811,384 patent/US10568927B2/en active Active
-
2020
- 2020-04-01 JP JP2020065913A patent/JP7219736B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3024474B1 (en) | 2022-01-05 |
| JP2020109122A (ja) | 2020-07-16 |
| AU2014293141A1 (en) | 2016-02-18 |
| KR20210103589A (ko) | 2021-08-23 |
| DK3024474T3 (da) | 2022-03-28 |
| JP7219736B2 (ja) | 2023-02-08 |
| US10568927B2 (en) | 2020-02-25 |
| US20150031613A1 (en) | 2015-01-29 |
| JP2016525548A (ja) | 2016-08-25 |
| EP3024474A1 (en) | 2016-06-01 |
| WO2015013454A1 (en) | 2015-01-29 |
| CA2919198A1 (en) | 2015-01-29 |
| KR20240015735A (ko) | 2024-02-05 |
| US9814753B2 (en) | 2017-11-14 |
| KR20160033220A (ko) | 2016-03-25 |
| US20180289769A1 (en) | 2018-10-11 |
| ES2910361T3 (es) | 2022-05-12 |
| CN105579057A (zh) | 2016-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267066B (en) | Activin-actrii antagonists and their use for the treatment of bone and other disorders | |
| SG11201705917PA (en) | Low density polishing pad | |
| IL240393B (en) | Il-33 antagonists and their uses | |
| GB2528622B (en) | Test bench combining high-frequency tribological stress and oligocyclic fatigue | |
| ZA201506131B (en) | Kv1.3 antagonists and methods of use | |
| PT3221514T (pt) | Palmilha de travessa | |
| SI3013855T1 (sl) | Mutantne sestave faktorja VIII in metode | |
| PL3437579T3 (pl) | Narzędzie kriochirurgiczne | |
| PL3215676T3 (pl) | Punkt mocujący szyny i płyty podkładowej | |
| PL3019242T3 (pl) | Kompozycje i sposoby leczenia zaburzeń neuropsychiatrycznych przy zastosowaniu agonisty receptora endoteliny-B | |
| SG11201505923QA (en) | Polishing pad | |
| IN2014CN00312A (enExample) | ||
| IL276431A (en) | Treatment of the brain disorders and related symptoms | |
| PL3452659T3 (pl) | Warstwa pośrednia szyny | |
| TWI563074B (en) | Nickel phosphorous cmp compositions and methods | |
| MX2016001032A (es) | Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa. | |
| MX2017006655A (es) | Metodos y composiciones que comprenden desmopresina en combinacion con un antagonista del receptor alfa-adrenergico. | |
| GB201405212D0 (en) | User equipment proximity requests | |
| GB201511162D0 (en) | Kneeling pad device | |
| GB201319775D0 (en) | Colourful and bright diamond | |
| GB2516844B (en) | Kneeling pad | |
| GB201609808D0 (en) | In situ woodwind pad | |
| GB201709497D0 (en) | Tele-dildonics through spherical harmonics | |
| ZA201606113B (en) | Composition for relieving pain, stress and insomnia | |
| TWM532797U (en) | Elastic pad structure |